Mirvetuximab 2025 Medical Insurance Reimbursement Policy

Somituximab(Mirvetuximab) is a new type of antibody drug conjugate (ADC), mainly used to treat patients with relapsed or refractory ovarian cancer with high FRα (folate receptor α) expression. In China, somituximab has been approved for marketing, but as of 2025, it has not yet been included in the medical insurance catalog. Because it is an imported innovative drug, the price of a single 100mg bottle is as high as about 110,000 yuan, which is a large financial burden for most patients. Therefore, patients need to fully assess their financial affordability when choosing medications and communicate with their doctors about treatment options.

The high price of somituximab reflects its R&D cost and the targeted nature of its treatment. As an antibody-drug conjugate, it delivers cytotoxic drugs directly to cancer cells by specifically binding to FRα receptors on the surface of tumor cells, thereby improving anti-tumor efficiency and minimizing damage to healthy tissues. This precise targeting mechanism makes somituximab show significant advantages in the treatment of recurrent ovarian cancer, especially for those patients who are resistant to chemotherapy or relapse. In overseas markets, somituximab is also a high-priced innovative drug, but it can be partially reimbursed by the medical insurance or Medicaid systems of some countries. Therefore, international experience can provide reference for domestic patients.

At present, if domestic patients want to receive somituximab treatment, they mainly rely on purchasing drugs at their own expense or obtaining imported drugs through international drug purchase channels. In clinical practice, doctors usually evaluate the patient's pathological type, FRα expression level, and previous treatment history before deciding whether to recommend the drug. For patients with clear indications and financial conditions permitting, somituximab provides a new treatment option that can play a positive role in controlling tumor progression and improving quality of life.

Reference materials:https://www.elahere.com/